NEW YORK, NY / ACCESSWIRE / November 15, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
ProPetro Holding Corp. (PUMP)
Class Period: on behalf of shareholders who purchased securities pursuant and/or traceable to the Company's registration statement and prospectus issued in connection with the Company's March 2017 initial public offering and/or between February 17, 2017 and August 8, 2019.
Lead Plaintiff Deadline: November 15, 2019
The complaint alleges that during the class period ProPetro Holding Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's executive officers were improperly reimbursed for certain expenses; (2) the Company had engaged in certain undisclosed transactions with related parties; (3) the Company lacked adequate disclosure controls and procedures; (4) the Company lacked effective internal control over financial reporting; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in PUMP: http://www.kleinstocklaw.com/pslra-1/propetro-holding-corp-loss-submission-form?id=4423&from=1
Match Group, Inc. (MTCH)
Class Period: August 6, 2019 to September 25, 2019
Lead Plaintiff Deadline: December 2, 2019
Throughout the class period, Match Group, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company used fake love interest ads to convince customers to buy and upgrade subscriptions; (2) the Company made it difficult and confusing for consumers to cancel their subscriptions; (3) as a result, the Company was reasonably likely to be subject to regulatory scrutiny; (4) the Company lacked adequate disclosure controls and procedures; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in MTCH: http://www.kleinstocklaw.com/pslra-1/match-group-inc-loss-submission-form?id=4423&from=1
Myriad Genetics, Inc. (MYGN)
Class Period: September 2, 2016 to August 13, 2019
Lead Plaintiff Deadline: November 26, 2019
During the class period, Myriad Genetics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Myriad's product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration ("FDA") had requested changes to GeneSight and questioned the validity of the test's purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA's requested changes to GeneSight; (iv) Myriad's acquisition of Counsyl-and thereby, Foresight-caused the Company to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on the Company's revenue; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in MYGN: http://www.kleinstocklaw.com/pslra-1/myriad-genetics-inc-loss-submission-form?id=4423&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com: